Issued: 1 June 2024, London
UK
Statement: Zantac (ranitidine) litigation - Delaware State
Court Daubert Ruling
· Scientific consensus is that there is no consistent or
reliable evidence that ranitidine increases the risk of any cancer
and GSK will continue to vigorously defend itself against all
claims
· Ruling to permit claims is not consistent with the Federal
Court's Multidistrict Litigation (MDL) ruling under the same legal
standard
· GSK disagrees with ruling by the Delaware State Court and will
immediately seek an appeal
GSK plc (LSE/NYSE: GSK)
disagrees with the ruling by the Delaware State
Court and will immediately seek an appeal. The decision by the
State Court contradicts the Federal Court's MDL ruling under the
same legal standard, which dismissed all cases alleging five cancer
types, in December 2022.
Following the 16 epidemiological
studies looking at human data regarding the use of ranitidine, the
scientific consensus is that there is no consistent or reliable
evidence that ranitidine increases the risk of any
cancer.
The litigation in Delaware remains
at an early stage, and the ruling, under the Daubert standard,
relates only to the question of whether the methodology used by
plaintiffs' experts is sufficiently reliable to allow them to
present their evidence at trial.
The ruling does not mean that the
Court agrees with plaintiffs' experts' scientific conclusions, and
it does not determine liability.
GSK will continue to vigorously
defend itself against all claims and manage this litigation in the
best interests of shareholders. Alongside immediately seeking an
appeal to the Delaware Supreme Court, the Company will file motions
for dismissal pressing additional defenses, severance of cases, and
proof-of-use by claimants; and, at the same time, the Company will
progress to trials of individual cases.
GSK's capital allocation priorities
remain unchanged, and the ruling has no impact on the Company's
investment plans for growth.
About GSK
GSK is a global biopharma company
with a purpose to unite science, technology, and talent to get
ahead of disease together. Find out more at gsk.com.
GSK
enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D "Risk factors" in GSK's
Annual Report on Form 20-F for 2023, and GSK's Q1 Results for
2024.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS